The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive

Francine H. Einstein, Rodney L. Wright, Stephanie Trentacoste, Susan Gross, Irwin R. Merkatz, Peter S. Bernstein

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The purpose of this study was to compare alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol levels in women who take protease inhibitors and those women who do not. This retrospective review from August 2000 to May 2003 was performed for maternal serum screen results, medication use, pregnancy, and perinatal outcomes. Thirty-nine women met study criteria. Sixteen women were treated with protease inhibitors, and 23 women were not treated with protease inhibitors. There was no difference in initial viral load or initial CD4 count between the groups. No difference was found for human chorionic gonadotropin and estriol levels; significantly lower alpha-fetoprotein multiples of the median were found for the women who were treated with protease inhibitors compared with the women who were not (0.97 ± 0.32 [SD] MoM vs 1.2 ± 0.4 MoM, respectively; P =. 04). Six of 39 women (15%) had positive maternal serum screens. All the babies were normal at birth, and there were no cases of perinatal transmission of human immunodeficiency virus. Protease inhibitors are associated with lower alpha-fetoprotein levels in women who are infected with human immunodeficiency virus.

Original languageEnglish (US)
Pages (from-to)1004-1008
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume191
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Protease Inhibitors
Pregnant Women
Mothers
HIV
Serum
alpha-Fetoproteins
Estriol
Chorionic Gonadotropin
Pregnancy Outcome
CD4 Lymphocyte Count
Viral Load
Parturition

Keywords

  • Alpha-fetoprotein
  • Highly active antiretroviral therapy
  • Human immunodeficiency virus
  • Maternal serum screening
  • Protease inhibitor

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive. / Einstein, Francine H.; Wright, Rodney L.; Trentacoste, Stephanie; Gross, Susan; Merkatz, Irwin R.; Bernstein, Peter S.

In: American Journal of Obstetrics and Gynecology, Vol. 191, No. 3, 09.2004, p. 1004-1008.

Research output: Contribution to journalArticle

@article{853c3a4266b9489cad94c13ad6333436,
title = "The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive",
abstract = "The purpose of this study was to compare alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol levels in women who take protease inhibitors and those women who do not. This retrospective review from August 2000 to May 2003 was performed for maternal serum screen results, medication use, pregnancy, and perinatal outcomes. Thirty-nine women met study criteria. Sixteen women were treated with protease inhibitors, and 23 women were not treated with protease inhibitors. There was no difference in initial viral load or initial CD4 count between the groups. No difference was found for human chorionic gonadotropin and estriol levels; significantly lower alpha-fetoprotein multiples of the median were found for the women who were treated with protease inhibitors compared with the women who were not (0.97 ± 0.32 [SD] MoM vs 1.2 ± 0.4 MoM, respectively; P =. 04). Six of 39 women (15{\%}) had positive maternal serum screens. All the babies were normal at birth, and there were no cases of perinatal transmission of human immunodeficiency virus. Protease inhibitors are associated with lower alpha-fetoprotein levels in women who are infected with human immunodeficiency virus.",
keywords = "Alpha-fetoprotein, Highly active antiretroviral therapy, Human immunodeficiency virus, Maternal serum screening, Protease inhibitor",
author = "Einstein, {Francine H.} and Wright, {Rodney L.} and Stephanie Trentacoste and Susan Gross and Merkatz, {Irwin R.} and Bernstein, {Peter S.}",
year = "2004",
month = "9",
doi = "10.1016/j.ajog.2004.05.046",
language = "English (US)",
volume = "191",
pages = "1004--1008",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive

AU - Einstein, Francine H.

AU - Wright, Rodney L.

AU - Trentacoste, Stephanie

AU - Gross, Susan

AU - Merkatz, Irwin R.

AU - Bernstein, Peter S.

PY - 2004/9

Y1 - 2004/9

N2 - The purpose of this study was to compare alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol levels in women who take protease inhibitors and those women who do not. This retrospective review from August 2000 to May 2003 was performed for maternal serum screen results, medication use, pregnancy, and perinatal outcomes. Thirty-nine women met study criteria. Sixteen women were treated with protease inhibitors, and 23 women were not treated with protease inhibitors. There was no difference in initial viral load or initial CD4 count between the groups. No difference was found for human chorionic gonadotropin and estriol levels; significantly lower alpha-fetoprotein multiples of the median were found for the women who were treated with protease inhibitors compared with the women who were not (0.97 ± 0.32 [SD] MoM vs 1.2 ± 0.4 MoM, respectively; P =. 04). Six of 39 women (15%) had positive maternal serum screens. All the babies were normal at birth, and there were no cases of perinatal transmission of human immunodeficiency virus. Protease inhibitors are associated with lower alpha-fetoprotein levels in women who are infected with human immunodeficiency virus.

AB - The purpose of this study was to compare alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol levels in women who take protease inhibitors and those women who do not. This retrospective review from August 2000 to May 2003 was performed for maternal serum screen results, medication use, pregnancy, and perinatal outcomes. Thirty-nine women met study criteria. Sixteen women were treated with protease inhibitors, and 23 women were not treated with protease inhibitors. There was no difference in initial viral load or initial CD4 count between the groups. No difference was found for human chorionic gonadotropin and estriol levels; significantly lower alpha-fetoprotein multiples of the median were found for the women who were treated with protease inhibitors compared with the women who were not (0.97 ± 0.32 [SD] MoM vs 1.2 ± 0.4 MoM, respectively; P =. 04). Six of 39 women (15%) had positive maternal serum screens. All the babies were normal at birth, and there were no cases of perinatal transmission of human immunodeficiency virus. Protease inhibitors are associated with lower alpha-fetoprotein levels in women who are infected with human immunodeficiency virus.

KW - Alpha-fetoprotein

KW - Highly active antiretroviral therapy

KW - Human immunodeficiency virus

KW - Maternal serum screening

KW - Protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=4644305827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644305827&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2004.05.046

DO - 10.1016/j.ajog.2004.05.046

M3 - Article

C2 - 15467580

AN - SCOPUS:4644305827

VL - 191

SP - 1004

EP - 1008

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -